Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CMO Rebecca Taub sold 2,676 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, April 8th. The stock was sold at an average price of $245.99, for a total value of $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company's stock, valued at approximately $112,909,164.01. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Rebecca Taub also recently made the following trade(s):
- On Wednesday, April 3rd, Rebecca Taub sold 27,845 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $245.14, for a total value of $6,825,923.30.
- On Friday, April 5th, Rebecca Taub sold 27,506 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $243.36, for a total value of $6,693,860.16.
Madrigal Pharmaceuticals Stock Performance
NASDAQ:MDGL opened at $244.67 on Thursday. The stock has a 50-day simple moving average of $240.93 and a two-hundred day simple moving average of $206.38. Madrigal Pharmaceuticals, Inc. has a 52-week low of $119.76 and a 52-week high of $322.67. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.38 and a current ratio of 5.38. The firm has a market capitalization of $4.87 billion, a PE ratio of -12.27 and a beta of -0.47.
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by ($0.42). During the same quarter last year, the company earned ($4.98) earnings per share. Analysts forecast that Madrigal Pharmaceuticals, Inc. will post -21.48 EPS for the current year.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. HC Wainwright lifted their target price on Madrigal Pharmaceuticals from $405.00 to $425.00 and gave the stock a "buy" rating in a report on Friday, March 15th. B. Riley raised Madrigal Pharmaceuticals from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $270.00 in a report on Friday, March 15th. Canaccord Genuity Group lifted their price objective on Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the stock a "buy" rating in a report on Friday, March 15th. Oppenheimer lifted their price objective on Madrigal Pharmaceuticals from $320.00 to $375.00 and gave the stock an "outperform" rating in a report on Friday, March 15th. Finally, Citigroup lifted their price objective on Madrigal Pharmaceuticals from $382.00 to $389.00 and gave the stock a "buy" rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $377.40.
Read Our Latest Stock Analysis on Madrigal Pharmaceuticals
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in shares of Madrigal Pharmaceuticals by 21.7% in the third quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the biopharmaceutical company's stock valued at $301,000 after acquiring an additional 367 shares in the last quarter. Glenmede Trust Co. NA lifted its position in shares of Madrigal Pharmaceuticals by 53.2% in the third quarter. Glenmede Trust Co. NA now owns 1,567 shares of the biopharmaceutical company's stock valued at $229,000 after acquiring an additional 544 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the third quarter valued at about $314,000. Charles Schwab Investment Management Inc. lifted its position in shares of Madrigal Pharmaceuticals by 11.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 109,501 shares of the biopharmaceutical company's stock valued at $15,992,000 after acquiring an additional 11,083 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Madrigal Pharmaceuticals by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company's stock worth $229,770,000 after buying an additional 107,816 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
